Immunological Risk Assessment Transplant Market

Pre-transplant assessment leads the immunological risk assessment transplant market with a 65.0% share in 2026, while HLA typing holds a 31.0% share. Market growth relies on advanced compatibility testing, molecular diagnostics, and transplant program adoption, with laboratory standardization, result interpretation, and long-term monitoring remaining important for wider clinical implementation.